Indication:

• Haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis like: Prostatectomy and bladder surgery, Menorrhagia, Epistaxis, Conisation of the cervix, Management of dental extraction in patients with coagulopathies,Ulcerative colitis, Haematuria,Gastrointestinalhaemorrhage.
• General fibrinolysis as in prostatic and pancreatic cancer, after thoracic and other major surgery, in obstetrical complications such as abruptio placentae and post-partum haemorrhage, in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase.
• Hereditary angioneuroticedema.
• Melasma, both dermal and epidermal melasma.

Dosage & Administration:

2-3, 500 mg tablets, two to three times daily for 4-14 days.

Preparation:

Fibrinic^® 500 Tablet: Box containing 10 × 10tablets in blister pack.
Fibrinic^® 250 Tablet: Box containing 10 × 10 tablets in blister pack.